The purpose of this study is to determine the optimal dose or doses of HM11260C, when administered once a week under the skin, to improve the control of blood sugar levels in patients with early-stage type 2 diabetes mellitus (T2DM).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
254
HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue)
Liraglutide is a GLP-1 agonist.
Placebo
Hanmi pharmaceutical
CA, California, United States
Change in baseline in glycosylated haemoglobin (HbA1c) at 12 weeks
Time frame: Up to 127 days
Fasting plasma glucose levels (FPG)
Time frame: Up to 127 days
7-point glucose profile
Time frame: Up to day 127
Other glycaemic control parameters
Time frame: Up to day 127
Serum lipid profile
Time frame: Up to day 127
Body weight
Time frame: Up to day 127
Number of subjects attaining goal glycosylated haemoglobin (HbA1c) <7%
Time frame: Up to 127 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.